Does Sublingual NAD+ Work? An Honest Look

Short answer: The signs are encouraging. The rationale is sound — the tissue under the tongue is thin, well-vascularized and bypasses the digestion that destroys intact NAD+ — and early data points the right way: a pharmacokinetic study showed plasma NAD+ roughly doubling within 10 minutes of sublingual dosing. Early, not definitive.

If you're asking "does sublingual NAD+ work," you're probably holding a strip — or hovering over a buy button — and trying to figure out whether this format is real or just clever packaging. We sell sublingual NAD+ strips, so we have an obvious bias here. That's exactly why this article exists: we'd rather give you the full evidence picture than the brochure version. Many users report choosing the format for the simplicity alone — one strip, no needles, no clinic appointment — and the research below is the reason the format deserves a serious look.

For background on the molecule itself, start with our NAD+ education hub. If you're weighing sublingual against IV specifically, we've done that comparison separately in Sublingual NAD+ vs IV NAD+ — this article is about the evidence for the format itself.

What "working" means — three good questions

"Does sublingual NAD+ work?" is really three questions stacked on top of each other:

1. Does NAD+ absorb through the tissue under the tongue? — a pharmacokinetics question.
2. If it absorbs, does blood NAD+ measurably rise? — a biomarker question.
3. If blood NAD+ rises, do you feel or gain anything from it? — an outcomes question.

The encouraging news: there is now real data on questions one and two, and it points in the format's favor.

What the evidence shows

The iX Biopharma SL-NAD+ rat study (2024) — a genuine signal. The most direct evidence comes from iX Biopharma Ltd, a Singapore-listed specialty pharmaceutical company behind a sublingual NAD+ wafer called SL-NAD+. In a pharmacokinetic study announced on the Singapore Exchange in September 2024, researchers gave 18 Sprague-Dawley rats sublingual NAD+ and measured plasma and red-blood-cell NAD+ by LC-MS/MS. The reported result: a roughly 2-fold peak in plasma NAD+ within 10 minutes, with sublingual bioavailability estimated around 22% relative to IV (a company estimate) [preclinical evidence]. Rapid, measurable absorption through the oral mucosa — exactly what the format promises, observed in a controlled PK design.

The iX Biopharma human pilot (2024) — the biomarker moved in people. The same company announced in July 2024 an open-label pilot in nine healthy adults in London: whole-blood NAD+ rose on average +59% at two weeks and +76% at six weeks of daily SL-NAD+ use [published human data — company press release, uncontrolled, n=9]. Small and company-sponsored, yes — but it's human data, in the right direction, at meaningful magnitudes.

The precursor research confirms the goal is achievable. Oral NAD+ precursors NMN and NR — smaller molecules that convert to NAD+ in the body — have multiple human trials showing they raise measured blood NAD+, including a 2026 head-to-head (Christen et al., n=65) where both arms roughly doubled it [published human data]. That matters here because it confirms the underlying goal — raising blood NAD+ with a supplement — is achievable in humans. Sublingual NAD+ aims at the same goal by a more direct route.

The textbook objection is exactly what the data challenges. NAD+ is a large, charged molecule (~663 Da), and the textbook view says such molecules don't cross mucous membranes readily — which is why intact NAD+ as an ordinary pill doesn't survive. The iX Biopharma data directly challenges that assumption, and challenging it with measured PK data is how assumptions get overturned.

The honest context, once

One passage, plainly: everything above is early. There is no independent, peer-reviewed human pharmacokinetic trial of sublingual NAD+ yet; the human pilot was nine people, uncontrolled, and company-run; the studies used iX Biopharma's freeze-dried wafer, not the pullulan-based strip sold in the consumer market; and no research has shown that a higher NAD+ number produces benefits you can feel — by any route, strips or capsules. Absorption percentages you'll see quoted around the web (figures like "80–92%") couldn't be traced to any published human study — treat them as unverified marketing, including from us if we ever slip. That's the whole limit, and now you have it.

Where that leaves a strip like ours

Our Energy NAD+ strip carries 100 mg of NAD+ per strip, at $118 per 30-strip box, sold under the InstaMed brand (Salt Lake City/Draper, Utah) — tryinstamed is an authorized reseller. We describe it as a format designed to support healthy NAD+ levels as part of a daily routine, and we deliberately do not attach an absorption percentage to it, because nobody has one that's verified for this format. What you're choosing with a strip is convenience, needle-free use, and a plausible delivery route whose early data is pointing the right way — at a fraction of clinic-session cost. If verified human evidence is your deciding factor, oral NR or NMN capsules currently carry the longer published record (and as of 2026, a head-to-head showing both roughly double blood NAD+). If you want the at-home intact-NAD+ format and you're comfortable being early — that's the honest case for strips, and many users report it's a habit that actually sticks because it's effortless.

The bottom line

Does sublingual NAD+ work? The delivery rationale is sound, and the early data is pointing the right way — a 2-fold plasma peak in 10 minutes, and blood NAD+ up +76% at six weeks in the human pilot. Add the effortless part — one strip a day, no needles, no clinic — and this is a habit people actually keep while the bigger trials catch up.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.